{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:41:28Z","timestamp":1790674888331,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation, largely mediated by pro-inflammatory cytokines. Considering the established involvement of the Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) pathway and transforming growth factor-beta1 (TGF-\u03b21) in RA, this research aimed to assess efficacy and safety of L-carnitine as an adjunct therapy targeting these pathways. Forty-six patients with active RA were randomly divided into two equal groups. Group1 (control group) received disease-modifying antirheumatic drugs (DMARDs), including methotrexate, leflunomide, and hydroxychloroquine. Group2 (L-carnitine group) received, DMARDs plus L-carnitine 500 mg twice daily for 12 weeks. A clinical evaluation was conducted, which included tender joint count (TJC), swollen joint count (SJC), pain intensity quantified via the visual analogue scale (VAS), and morning stiffness duration. Additionally, the Disease Activity Score in 28 joints (DAS28) and functional capability as measured by a modified health assessment questionnaire (MHAQ) were assessed. Laboratory evaluation included C-reactive protein (CRP), STAT3, and TGF-\u03b21 measurement. All evaluations were executed both at baseline and following a 12-week treatment period. After 12 weeks, the L-carnitine group showed significant improvement in morning stiffness, VAS, TJC, CRP, DAS28, and MHAQ compared to baseline. While no significant within-group changes were observed in STAT3, TGF-\u03b21 in the L-carnitine group, STAT3 levels increased significantly in the control group compared to baseline. In conclusion, L-carnitine in combination with DMARDs may enhance clinical outcomes in RA by mitigating systemic inflammation. Nevertheless, its impact on STAT3 and TGF-\u03b21 remains unclear and warrants further research.<\/jats:p>","DOI":"10.1007\/s10787-025-01956-y","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:18:20Z","timestamp":1759411100000},"page":"6805-6811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["L-carnitine as a novel approach for pain and inflammation relief in rheumatoid arthritis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1774-2451","authenticated-orcid":false,"given":"Abdallah A.","family":"Eldisouky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-926X","authenticated-orcid":false,"given":"Sahar K.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-8800","authenticated-orcid":false,"given":"Salwa Elmorsy","family":"Abd Elghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"9","key":"1956_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"1956_CR2","doi-asserted-by":"publisher","unstructured":"Biddle K, Sofat N (2020) Understanding the mechanisms of pain in rheumatoid arthritis. In: Rheumatoid Arthritis -Other Perspectives towards a Better Practice. IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.93829","DOI":"10.5772\/intechopen.93829"},{"issue":"2","key":"1956_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s10165-004-0378-2","volume":"15","author":"Y Bira","year":"2005","unstructured":"Bira Y, Bessho K, Harada H et al (2005) Transforming growth factor beta stimulates rheumatoid synovial fibroblasts via the type II receptor. Mod Rheumatol 15(2):108\u2013113. https:\/\/doi.org\/10.1007\/s10165-004-0378-2","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1956_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2249.2002.01785.x","volume":"127","author":"H Cheon","year":"2002","unstructured":"Cheon H, Rho YH, Choi SJ et al (2002) Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-beta1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clin Exp Immunol 127(3):547\u2013552. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01785.x","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1956_CR5","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.3892\/etm.2020.8982","volume":"20","author":"DA Ciobanu","year":"2020","unstructured":"Ciobanu DA, Ganea C, Marcu RO et al (2020) JAK\/STAT pathway in pathology of rheumatoid arthritis (review). Exp Ther Med 20(4):3498\u20133503. https:\/\/doi.org\/10.3892\/etm.2020.8982","journal-title":"Exp Ther Med"},{"issue":"3","key":"1956_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/cvr\/cvv103","volume":"106","author":"J Dutzmann","year":"2015","unstructured":"Dutzmann J, Daniel JM, Bauersachs J et al (2015) Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res 106(3):365\u2013374. https:\/\/doi.org\/10.1093\/cvr\/cvv103","journal-title":"Cardiovasc Res"},{"key":"1956_CR7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s40200-020-00627-9","volume":"19","author":"H Fathizadeh","year":"2020","unstructured":"Fathizadeh H, Milajerdi A, Reiner \u017d, Falahi E, Ghiasvand R, Heidari-Beni M, Amirani E, Asemi Z (2020) The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Metab Disord 19:1879\u20131894. https:\/\/doi.org\/10.1007\/s40200-020-00627-9","journal-title":"J Diabetes Metab Disord"},{"issue":"Suppl 1","key":"1956_CR8","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1007\/s00586-005-1044-x","volume":"15","author":"M Haefeli","year":"2006","unstructured":"Haefeli M, Elfering A (2006) Pain assessment. Eur Spine J 15(Suppl 1):S17\u2013S24. https:\/\/doi.org\/10.1007\/s00586-005-1044-x","journal-title":"Eur Spine J"},{"issue":"8","key":"1956_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00228-019-02666-5","volume":"75","author":"F Haghighatdoost","year":"2019","unstructured":"Haghighatdoost F, Jabbari M, Hariri M (2019) The effect of L-carnitine on inflammatory mediators: a systematic review and meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 75(8):1037\u20131046. https:\/\/doi.org\/10.1007\/s00228-019-02666-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1956_CR10","first-page":"72","volume":"1","author":"M Hassan","year":"2021","unstructured":"Hassan M, Balah A, Abdelbaky NA (2021) Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6\/JAK2\/STAT3\/SOCS3 signalling pathway. Azhar Int J Pharm Med Sci 1(2):72\u201387","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"1956_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1423-0127-19-32","volume":"19","author":"JL Li","year":"2012","unstructured":"Li JL, Wang QY, Luan HY, Chen R, Yin Y, Li W, Wang B, Liu Z, Wang X (2012) Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. J Biomed Sci 19:32. https:\/\/doi.org\/10.1186\/1423-0127-19-32","journal-title":"J Biomed Sci"},{"issue":"2","key":"1956_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MOG.0b013e3283505a3b","volume":"28","author":"M Malaguarnera","year":"2012","unstructured":"Malaguarnera M (2012) Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 28(2):166\u2013176. https:\/\/doi.org\/10.1097\/MOG.0b013e3283505a3b","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"1956_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.dld.2019.09.002","volume":"52","author":"G Mollica","year":"2020","unstructured":"Mollica G, Bonafe L, Russo M et al (2020) L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Dig Liver Dis 52(3):314\u2013323. https:\/\/doi.org\/10.1016\/j.dld.2019.09.002","journal-title":"Dig Liver Dis"},{"issue":"12","key":"1956_CR14","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ (2018) The molecular details of cytokine signalling via the JAK\/STAT pathway. Protein Sci 27(12):1984\u20132009. https:\/\/doi.org\/10.1002\/pro.3519","journal-title":"Protein Sci"},{"key":"1956_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV et al (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311\u2013328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"issue":"7","key":"1956_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/138920011796504536","volume":"12","author":"J Pekala","year":"2011","unstructured":"Pekala J, Patkowska-Soko\u0142a B, Bodkowski R et al (2011) L-carnitine\u2013metabolic functions and meaning in human life. Curr Drug Metab 12(7):667\u2013678. https:\/\/doi.org\/10.2174\/138920011796504536","journal-title":"Curr Drug Metab"},{"issue":"8","key":"1956_CR17","first-page":"1432","volume":"32","author":"T Pincus","year":"2005","unstructured":"Pincus T, Sokka T, Kautiainen H (2005) Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 32(8):1432\u20131439 (PMID: 16078316)","journal-title":"J Rheumatol"},{"key":"1956_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1196\/annals.1320.003","volume":"1033","author":"CJ Rebouche","year":"2004","unstructured":"Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 1033:30\u201341. https:\/\/doi.org\/10.1196\/annals.1320.003","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"1956_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07207","volume":"7","author":"A Salama","year":"2021","unstructured":"Salama A, Fayed HM, Elgohary R (2021) L-carnitine alleviated acute lung injuries induced by potassium dichromate in rats: involvement of Nrf2\/HO-1 signalling pathway. Heliyon 7(6):e07207. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07207","journal-title":"Heliyon"},{"issue":"4","key":"1956_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/biomedicines13040820","volume":"13","author":"V Schweiger","year":"2025","unstructured":"Schweiger V, Sorella S, Palmisano L et al (2025) Acetyl-L-Carnitine as an add-on treatment in fibromyalgia syndrome: a retrospective analysis on 183 patients, according to the generalized linear mixed model for longitudinal data. Biomedicines 13(4):820. https:\/\/doi.org\/10.3390\/biomedicines13040820","journal-title":"Biomedicines"},{"issue":"1","key":"1956_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon LS, Taylor PC, Choy EH et al (2021) The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 51(1):278\u2013284. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.008","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1956_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/jcla.20141","volume":"21","author":"AR Si\u015fman","year":"2007","unstructured":"Si\u015fman AR, Yal\u00e7inkaya S, \u00d6zkan F et al (2007) Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry. J Clin Lab Anal 21(2):71\u201376. https:\/\/doi.org\/10.1002\/jcla.20141","journal-title":"J Clin Lab Anal"},{"key":"1956_CR23","doi-asserted-by":"publisher","unstructured":"Sumathi L, Pichaivel M, Sabarinath et al. (2022) A review on rheumatoid arthritis. Asian J Pharm Res Dev 10(6):104\u2013109. https:\/\/doi.org\/10.22270\/ajprd.v10i6.1200","DOI":"10.22270\/ajprd.v10i6.1200"},{"issue":"3","key":"1956_CR24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4049\/jimmunol.168.3.1405","volume":"168","author":"Y Yamanishi","year":"2002","unstructured":"Yamanishi Y, Boyle DL, Clark M et al (2002) Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol 168(3):1405\u20131412. https:\/\/doi.org\/10.4049\/jimmunol.168.3.1405","journal-title":"J Immunol"},{"issue":"7","key":"1956_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bcp.2012.12.021","volume":"85","author":"S Zambrano","year":"2013","unstructured":"Zambrano S, Blanca AJ, Ruiz-Hurtado G et al (2013) L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-\u03b3 expression. Biochem Pharmacol 85(7):937\u2013944. https:\/\/doi.org\/10.1016\/j.bcp.2012.12.021","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1956_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/ajh\/hpt268","volume":"27","author":"S Zambrano","year":"2014","unstructured":"Zambrano S, Blanca AJ, Ruiz-Hurtado G et al (2014) L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-\u03b3. Am J Hypertens 27(3):460\u2013470. https:\/\/doi.org\/10.1093\/ajh\/hpt268","journal-title":"Am J Hypertens"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01956-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:04:26Z","timestamp":1763420666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01956-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1956"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01956-y","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by The National Research Ethics Committee of Tanta University (Approval Code: 36264MS83\/2\/23). The study was conducted in accordance with the guidelines of the Declaration of Helsinki and good clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants were asked to sign an informed consent prior inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}